Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C

Cancer Research

Volumn 56, Issue 4, 1996, Pages 802-808

  Zhang, Xueshu ^a,f   Zhang, Ruiwen ^a,b   Zhao, Hui ^a   Cai, Hongying ^a   Gush, Kimberly A ^d   Kerr, Russell G ^d   Pettit, George R ^e   Kraft, Andrew S ^c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d FLORIDA ATLANTIC UNIVERSITY   (United States)

^e ARIZONA STATE UNIVERSITY   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN 1; PROTEIN KINASE C ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STABILITY; ENZYME ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME ACTIVATION; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LACTONES; MACROLIDES; MICE; MICE, INBRED STRAINS; PROTEIN KINASE C; TIME FACTORS; TISSUE DISTRIBUTION; TRITIUM;

EID: 0030063389     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Pettit, G. R , Herald, S. L., Doubek, D. L., Arnold, E., and Clardy, J. Isolation and structure of bryostatin 1. J. Am. Chem. Soc., 104: 6846-6848, 1982.
2. Kraft, A. S., Smith, J. B., and Berkow, R. L. Bryostatin, an activator of calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic HL-60 cells Proc. Natl. Acad. Sci. USA. 83: 1334-1338, 1986.
3. Lilly, M., Tompkins, C , Brown, C., Pettit, G., and Kraft, A. S. Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin. Cancer Res , 50: 5520-5525, 1990.
4. Kraft, A. S., Williams, F., Pettit, G R , and Lilly, M. B. Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res., 49: 1287-1293, 1989.
5. Gignac, S. M., Bushie, M., Pettit, G R., Hoffbrand, A. V , and Drexler, H. G Expression of proto-oncogene c-jun during differentiation of B-chronic lymphocytic leukemia cells. Blood, 74: 1747-1757, 1989.
6. Drexler, H. G., Gignac, S. M., Johns, R. A., Scott, C. S., Pettit, G. R., and Hoffbrand, A. V. Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia. Leukemia (Baltimore), 4: 441-444, 1990.
7. Stone, R. M., Sariban, E , Pettit, G. R , and Kufe, D. W. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood, 72 208-213, 1988.
8. Asiedu, C., Biggs, J., Lilly, M., and Kraft, A. S. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res., 55: 3716-3720, 1995.
9. Philip, P. A., Rea, D., Thavasu, P., Carmichael, J. Stuart, N. S. A., Rockett, H., Talbot, D. C., Ganesan, T., Pettit, G. R., Balkwill, F , and Harris, A. L. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor induction in vivo. J. Natl. Cancer Inst., 85: 1812-1818, 1993.
10. Kraft, A. S., Woodley, S., Pettit, G. R , Gao, F., Coll, J. C., and Wagner, F. Comparison of the antitumor activity of bryostatin 1, 5, and 8. Cancer Chemother. Pharmacol , in press, 1995.
11. Mohr, H , Pettit, G. R., and Plessing-Menze, A. Co-induction of lymphokine synthesis by the antineoplastic bryostatins. Immunobiology, 175: 420-430, 1987.
12. Pettit, G. R. The bryostatins. In: W. Herz, G. W. Kirby, W. Steglich, and C. Tamm (eds.), Progress in the Chemistry of Organic Natural Products, Vol. 57, pp. 154-195. Vienna: Springer-Verlag, 1991.
13. Schuchter, L. M., Esa, A. H., May, W S., Laulis, M. K , Pettit, G. R , and Hess, A. D. Successful treatment of murine melanoma with bryostatin 1. Cancer Res., 51: 682-687, 1991.
14. Prendiville, J , Crowther, D., Thatcher, N., Woll, P. J., Fox, B. W., McGown, A., Testa, N., Stern, P., McDermott, R., Potter, M., and Pettit, G. R A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br. J. Cancer, 68: 418-424, 1994.
15. 3H]epibryostatin to protein kinase C. Cancer Commun , 3 67-70, 1991.
16. Zhang, R., Soong, S-j , Liu, T., Barnes, S., and Diasio, R. B. Pharmacokinetics and tissue distribution of 2-fluoro-β-alanine: possible relevance to toxicity pattern of 5-fluorouracil Drug Metab. Disp., 20: 113-119, 1992.
17. Zhang, R., Diasio, R. B., Lu, Z., Liu, T. P., Jiang, Z., Galbraith, W. M., and Agrawal, S. Pharmacokinetics and tissue disposition in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-I. Biochem. Pharmacol., 49: 929-939, 1995.
18. Liu, T. Characteristics of pharmacokinetics modeling in a phase I clinical trial of radiolabeled monoclonal antibody. Controlled Clin. Trials, 12: 654-655, 1991.